Evidence map›Paper›PMID 28204869›Full record

ReviewDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2017

[Corneal cell therapy-an overview].

M Fuest, G Hin-Fai Yam, G Swee-Lim Peh, P Walter, N Plange, J S Mehta

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Engineering of Human Corneal Endothelial CellsInternational journal of medical sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M FuestKlinik für Augenheilkunde, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland. mfuest@ukaachen.de.
G Hin-Fai YamTissue Engineering and Stem Cell Group, Singapore Eye Research Institute, Singapur, Singapur.
G Swee-Lim PehTissue Engineering and Stem Cell Group, Singapore Eye Research Institute, Singapur, Singapur.
P WalterKlinik für Augenheilkunde, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland.
N PlangeKlinik für Augenheilkunde, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland.
J S MehtaTissue Engineering and Stem Cell Group, Singapore Eye Research Institute, Singapur, Singapur.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the cultivation and expansion of primary corneal cells has made significant progress. The transplantation of cultured limbal epithelial cells represents a successful and established treatment of the ocular surface. Cultivated corneal endothelial cells are undergoing a clinical trial in Japan. Stromal keratocytes can now be expanded in vitro. A wide range of stem cell sources is being tested in vitro and animal models for their possible application in corneal cell therapy. This article gives an overview of recent advancements and prevailing limitations for the use of different cell sources in the therapy of corneal disease.

Indexed as

AnimalsCell- and Tissue-Based TherapyCells, CulturedCorneal KeratocytesCorneal StromaDisease Models, AnimalEndothelium, CornealEpithelium, CornealHumansIn Vitro TechniquesLimbus CorneaeStem Cell TransplantationTissue EngineeringCell therapyCorneaStem cellTissue engineeringTransplantation

Identifiers

PMID28204869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.